Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1641 1642 1643 1644 1645 1646 1647 1651 1671
This examiner grants 38% of resolved cases
Vanessa L. Ford serves in Tech Center 1600 and Art Unit 1600, where she has 222 resolved cases. Her allowance rate is 38.3 percent, indicating a rigorous standard for patentability. The median days to allowance is 1507, which reflects a long timeline for applications that are eventually granted. These 222 resolved cases provide a solid foundation for analyzing her examination tendencies.
The interview lift for this examiner is 38.4 percent, which is nearly identical to the base allowance rate. This suggests that conducting an interview effectively increases the chance of receiving an allowance compared to cases where no interview occurs. Practitioners should weigh the 38.4 percent lift against the 38.3 percent allowance rate and the 1507 median days to allowance when planning their strategy. The data from 222 resolved cases highlights the importance of direct communication in this art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18166878 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | Final Rejection | Janssen Biotech, Inc. |
| 18245819 | MOLECULES WITH SOLUBILITY TAG AND RELATED METHODS | Non-Final OA | Merck Patent GmbH |
| 18265694 | COSMETIC, NUTRACEUTICAL OR DERMATOLOGICAL USE OF A LACTOBACILLUS CRISPATUS STRAIN AND/OR OF A COMPOSITION COMPRISING SAME | Non-Final OA | BASF Corporation |
| 17603921 | Methods for Treatment of Subjects with Psoriatic Arthritis | Non-Final OA | Sun Pharmaceutical Industries Limited |
| 17938846 | METHODS OF TREATING NEW-ONSET PLAQUE TYPE PSORIASIS USING IL-17 ANTAGONISTS | Non-Final OA | NOVARTIS AG |
| 18800977 | SELECTIVE REDUCTION OF CYSTEINE RESIDUES IN IL-17 ANTIBODIES | Non-Final OA | Novartis Pharma AG |
| 18554108 | COMPOSITION FOR INHIBITING BIOFILM COMPRISING LACTOBACILLUS RHAMNOSUS AS ACTIVE INGREDIENT | Non-Final OA | Chr. Hansen A/S |
| 18275849 | NGF ISOFORM FOR USE IN THE TREATMENT OF OCULAR PATHOLOGIES | Non-Final OA | DOMPE' FARMACEUTICI SPA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy